ArriVent BioPharma faces investigation over clinical trial disclosure

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for purchasers of ArriVent BioPharma, Inc. The investigation centers on whether ArriVent adequately disclosed information regarding the progress of its clinical trial and the timing of negative efficacy data. This follows the company's announcement on October 6, 2026, that its Phase 3 FURVENT trial failed to meet its primary endpoint of progression-free survival. The stock price declined approximately 50% to 63% during the trading session after the trial failure was announced.

The investigation relates to the company's disclosures made while it was supporting an at-the-market offering of up to $250 million in a May 11, 2026 prospectus. The failure of the Phase 3 trial, which evaluated firmonertinib, significantly impacted the company's valuation and market standing.